DrugBiological
Abituzumab clinical trials
Also written EMD 525797.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2009 (2)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 2 |
| 2011 | 2 |
| 2016 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 0
Merck KGaA, Darmstadt, Germany (4) · EMD Serono (1) · EMD Serono Research & Development Institute, Inc. (1) · SFJ Pharmaceuticals X, LTD. (1)
Studies
Open first, then newest update. How each study uses Abituzumab is read from its arms, and is right about nine times in ten.
Testing it · 7
- Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer.WithdrawnPhase 2SFJ Pharmaceuticals X, LTD.NCT03688230Written as abituzumab
- Abituzumab in SSc-ILDTerminatedPhase 2EMD Serono Research & Development Institute, Inc.NCT02745145Written as Abituzumab 1500 mg
- A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate CancerCompletedPhase 1Merck KGaA, Darmstadt, GermanyNCT00958477Written as EMD 525797
- A Study of EMD525797 in Solid Tumor Patients in JapanCompletedPhase 1Merck KGaA, Darmstadt, GermanyNCT01327313Written as EMD525797
- EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal CancerCompletedPhase 1/2Merck KGaA, Darmstadt, GermanyNCT01008475Written as EMD 525797 250 mg
- EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate CancerCompletedPhase 2EMD SeronoNCT01360840Written as EMD 525797
- EMD 525797 in Colorectal and Ovarian Cancer Patients With Liver MetastasesCompletedPhase 1Merck KGaA, Darmstadt, GermanyNCT00848510Written as EMD 525797
Codes
What other systems call Abituzumab · ClinicalTrials.gg INT000113
- MeSH (NLM) C000592911AbituzumabOne source NLM
- UNII (FDA) 724QD330RDABITUZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q25101921abituzumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C82422AbituzumabOne source FDA
- DrugBank DB12775One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000592911 | Abituzumab | One source NLM |
| UNII (FDA) | 724QD330RD | ABITUZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q25101921 | abituzumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C82422 | Abituzumab | One source FDA |
| DrugBank | DB12775 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.